dMCL1-2

Target: Targets MCL1 anti-apoptotic BCL-2 family protein for experimental targeted protein degradation studies.

Binding Site: Binds the MCL1 BH3-binding groove and recruited E3 ligase ligand site to support productive ternary complex formation.

Mechanism of Action: dMCL1-2 is designed for use in PROTAC or targeted protein degradation experiments directed toward MCL1 anti-apoptotic BCL-2 family protein. The bifunctional molecule links a target-recognition element to cereblon, promoting proximity between the protein of interest and ubiquitination machinery. Productive ternary-complex formation can drive polyubiquitination and proteasome-dependent target depletion, allowing researchers to compare pharmacological inhibition with protein removal. It is suitable for evaluating degradation potency, kinetics, pathway selectivity, and downstream signaling consequences in engineered or disease-relevant cellular models.

• PROTAC-Mediated MCL1 Degradation: dMCL1-2 is a potent tool for researchers aiming to study the degradation of MCL1, an anti-apoptotic protein. By facilitating the ubiquitination and subsequent proteasomal degradation of MCL1, dMCL1-2 helps elucidate its role in cell survival pathways, offering insights into cancer biology and potential therapeutic targets.

• Targeted Protein Degradation in Oncology: Utilizing dMCL1-2 enables detailed investigation into the selective degradation of MCL1, a key player in tumorigenesis. Researchers can explore its impact on cancer cell viability and resistance mechanisms, advancing our understanding of targeted protein degradation strategies in oncological research.

• Mechanistic Studies of PROTACs: dMCL1-2 serves as an exemplary molecule for studying the mechanistic aspects of PROTAC technology. By observing its interaction with the ubiquitin-proteasome system, scientists can gain valuable insights into the design and optimization of PROTACs for various protein targets, enhancing the field of targeted protein degradation.